Pharma News

Abeona Therapeutics Inc.a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced updated data from the ongoing gene therapy clinical trial for Sanfilippo syndrome Type A (MPS IIIA) at the American Society Gene and Cell Therapy (ASGCT) 20th Annual Meeting. The ongoing Phase 1/2 trial for ABO-102 (AAV-SGSH) is a first-in-man clinical trial utilizing a single intravenous injection of AAV gene therapy for subjects with Sanfilippo syndrome (MPS IIIA), a rare autosomal-recessive lysosomal storage disease.

Scientists have developed a new energy storage device that works with fluids in the human body and could lead to more durable and battery-free pacemakers and other implantable medical devices. The bio-friendly energy storage system called biological supercapacitor is powered by charged particles, or ions, from body fluids like blood serum and urine. Pacemakers - which help regulate abnormal heart rhythms - and other implantable devices have saved countless lives.

Plans are underway to open the Jan Aushadhi stores to about 1,000 major railway stations in India as part of the government's commitment to make quality medicines available at low cost to the public. Plans are also underway to open such outlets in bus stands in different states with the aim of bringing the network back to small towns and villages.

Tonix Pharmaceuticals Holding Corp. a company that is developing innovative pharmaceutical products to address public health challenges, announced it will present additional analyses of data from its Phase 2 study in military-related posttraumatic stress disorder, or PTSD, at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) on May 20, 2017 in San Diego.

Medrobotics Corp., a medical robotics company, announced at the Royal Australasian College of Surgeons meeting in Adelaide that it has received TGA regulatory clearance to market the Flex® Robotic System for colorectal procedures. Medrobotics is the first and only company to offer minimally invasive, steerable and shapeable robotic products for colorectal procedures in Australia. The Flex® Robotic System is the world’s first robotic surgical platform to offer Scarfree™ access to hard-to-reach anatomy in otolaryngology and colorectal procedures. This provides surgeons treatment options that may not be possible with straight, rigid instruments.

[adsense:336x280:8701650588]

Burcon NutraScience Corporation is pleased to announce that it has been granted a U.S. patent, covering technology for the production of its Peazazz® pea protein:  U.S. patent no. 9,635,875, was granted on May 2, 2017.  This patent is the first to be granted for Burcon’s pea technology by the United States Patent and Trademark Office and confirms that the Company’s approach is unique, distinct and defensible.  Burcon anticipates further positive progress, with its patent filings, in due course.

AstraZeneca and MedImmune, its global biologics research and development arm,  announced that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate (AAER) in the overall population of severe, uncontrolled asthma patients, compared with placebo in STRATOS 1, the first of two pivotal Phase III trials.

Torrent Pharma, announced that it has completed the acquisition of Regestrone and Pregachieve brands for India from global Pharma player Novartis AG, Switzerland.

Biocon's Bengaluru plant had inspected by USFDA between March 27 to April 7, 2017 and USFDA issued form no. 483 to Biocon, largest biotechnology company of India. USFDA observed total 8 issues which were shared with the company. Shares of Biocon fell down after this reports circulated in media.

In what may be a relief for more than 1 lakh thalassemia patients in India, a public-sector stem cell bank should report to King George's Medical University from here. A project of the university's transfusion medicine department, the stem cell bank will deploy stem cell therapy in patients with thalassemia and sickle cell anemia. The proposal is awaiting authorization from the State Department of Medical Education.